Laboratory investigations in hemostasis

Development, validation and implementation of new laboratory diagnostic tools for the monitoring of hemostasis and bleeding disorders

Principal Investigator

Prof. Jonathan Douxfils

UNamur, Department of pharmacy 

Member of the Namur Thrombosis & Hemostasis Center (NTHC)

CEO and Founder of QUALIblood s.a.*

Research portal UNamur  |  ORCID  |  ResearchGate  |  LinkedIn

Expertise and research interests

After being graduated in pharmaceutical sciences in 2011, Prof. Jonathan Douxfils obtained his PhD in biomedical and pharmaceutical sciences in 2015.

In 2017 he launched QUALIblood, a Contract Research Organization (CRO) aiming to provide the industries, hospitals and universities with central laboratory services for blood investigations. His company employs 10 people actively working on pre-clinical, phase-2 and phase-3 clinical trials in several pharmaceutical fields.

In 2018, he gained an academic position at the University of Namur in Belgium.

In 2019, he received the Eberhard F. Mammen Young Investigator Award for his research on the development of a new algorithm based on thrombin generation to assess hormone-related prothrombotic changes.

In 2020, he was nominated as the “Namurois of Year”, category Sciences, a price rewarding people in the Namur community for their engagement and their scientific discovery.

During the COVID pandemic, in order to counter the wave of fraudulent in vitro diagnostic medical devices (IVD) that reached the market for only profit-benefit, he started several projects aiming at providing the laboratory with independent data on the performance of diagnostic assays. He started with his teams clinicals studies aiming at evaluating the serological response of COVID-19 patients and in vaccine recipients. He also started research on the risk of thrombotic events related to the cytokine storm.

The research directed by Prof. Douxfils played a leading role in the establishment of guidelines for the laboratory measurement of direct oral anticoagulants (DOACs). These recommendations have been used so far by several Expert Societies involved in the field of thrombosis and hemostasis. He also provided his expertise for the development of a new contraceptive agent and has been actively involved in the discussion and the writing of the regulatory documents for the obtention of the marketing authorization.

He also exercised his expertise as a pharmacovigilance expert at the European Medicines Agency, has been co-chairmen of the SSC Control of Anticoagulation at the International Society of Thrombosis and Haemostasis (ISTH), is Member Expert Team Haemostasis Diagnostics at the ECAT, and he works as an Associate Editor in several scientific journals.

Passionate about clinical and laboratory research, he is involved in several projects aiming to solve pharmacological and/or epidemiological problems.

Thanks to his translational view of the pharmaceutical and medical device market from basic research to post-marketing pharmacovigilance, his collaborations with key opinion leaders but also with field practitioners, Prof. Jonathan Douxfils puts its expertise and know-how at the services of societal projects aiming to improve the safety and effectiveness of therapeutic agents in order to promote public health.

Group members

PhD students: Marie Didembourg*, Jonathan Evrard, Julien Favresse (Clinical biologist at Clinique Saint-Luc Bouge), Constant Gillot, Hélène Haguet, Laure Morimont* and Lorian Ronvaux.

Research projects

  • ONGOING Simulation Glio. Ongoing PhD thesis by Lorian Ronvaux. Joint PhD programme at UNamur (Prof. Jonathan Douxfils) and Belgian Volition (Dr. Marielle Herzog).
  • ONGOING The THROMBIMMUN project: Relationship between inflammation, immunity and thrombosis. Ongoing PhD thesis by Constant Gillot. Under co-supervision by Prof. Jonathan Douxfils, UNamur, NARILIS (promoter) and Prof. Jean-Michel Dogné, UNamur, NARILIS (co-promoter).
  • ONGOING The HIC project: Evaluation of hormone-induced coagulopathy. Ongoing PhD theses by Laure Morimont* and Marie Didembourg*. Under co-supervision by Prof. Jonathan Douxfils, UNamur, NARILIS (promoter) and Prof. Jean-Michel Dogné, UNamur, NARILIS (co-promoter).
  • ONGOING The CAF project: A new tool for the assessment of the clot formation. Ongoing PhD thesis by Jonathan Evrard. Under co-supervision by Prof. Jonathan Douxfils, UNamur, NARILIS (promoter) and Prof. Jean-Michel Dogné, UNamur, NARILIS (co-promoter).
  • ONGOING The TiTKI project: Evaluation of the risk of thrombosis associated with the use of tyrosine kinase inhibitors. Ongoing PhD thesis by Hélène Haguet. Under co-supervision by Prof. Jonathan Douxfils, UNamur, NARILIS (promoter), Prof. Jean-Michel Dogné, UNamur, NARILIS (co-promoter) and Prof. François Mullier, CHU UCL Namur, Hematology laboratory (co-promoter).
  • ONGOING The MAS project: Measure And See the activity of direct oral anticoagulant in the clinical context. Research collaboration between UNamur (Prof. Jonathan Douxfils, Prof. Jean-Michel Dogné, Romain Siriez), Clinique Saint-Luc Bouge (Julien Favresse) and CHU UCL Namur (Prof. François Mullier and Dr. Michaël Hardy).
  • ONGOING The AVRI project: Evaluation of the risk of radiotherapy-induced atherosclerosis. Research collaboration between UNamur (Prof. Jonathan Douxfils, Prof. Jean-Michel Dogné, Dr. Céline Bouvy) and ULiège (Prof. Cécile Oury, Nathalie Donis).
SARS-CoV-2
  • ONGOING Evaluation of serological response after SARS-CoV-2 infection and vaccination. Ongoing PhD thesis by Julien Favresse (Clinical biologist at Clinique Saint-Luc Bouge). Under the supervision of Prof. Jonathan Douxfils, UNamur, NARILIS.
  • ONGOING The COVIMOA project: Collecting blood for SARS-CoV-2 virus detection and serological investigation. Research collaboration between UNamur (Prof. Jonathan Douxfils, Hélène Haguet), QUALIblood (Prof. Jonathan Douxfils and Clara David), Clinique Saint-Pierre Ottignies (Jean-Louis Bayart) and Clinique Saint-Luc Bouge (Julien Favresse).
  • ONGOING The COVILAB project: Clinical laboratory investigations related to COVID-19. Research collaboration between UNamur (Prof. Jonathan Douxfils, Prof. Jean-Michel Dogné, Hélène Haguet, Constant Gillot and Laure Morimont), QUALIblood (Prof. Jonathan Douxfils, Céline Bouvy, Laure Morimont and Sabrina Melchionda), Clinique Saint-Luc Bouge (Julien Favresse), Hôpitaux Iris Sud (Dr. Marie Tre-Hardy), and CHU UCL Namur (Prof. François Mullier and Dr. Michaël Hardy).

Selected publications

Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, Eeckhoudt SV, Roy T, Wieers G, Laurent C, Dogné JM, Closset M, Douxfils J. Antibody titers decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect. 2021 Jul 7:1-8.

Favresse J, Gillot C, Oliveira M, Cadrobbi J, Elsen M, Eucher C, Laffineur K, Rosseels C, Van Eeckhoudt S, Nicolas JB, Morimont L, Dogné JM, Douxfils J. Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection. J Clin Med. 2021 Jan 13;10(2):E265.

Douxfils J, Favresse J, Dogné JM, Lecompte T, Susen S, Cordonnier C, Lebreton A, Gosselin R, Sié P, Pernod G, Gruel Y, Nguyen P, Vayne C, Mullier F. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thromb Res. 2021 Jul;203:163-171.

Evrard J, Hardy M, Dogné JM, Lessire S, Maloteau V, Mullier F, Douxfils J. Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing. Int J Lab Hematol. 2021 Feb;43(1):e48-e51.

Haguet H, Bouvy C, Delvigne AS, Modaffari E, Wannez A, Sonveaux P, Dogné JM, Douxfils J. The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. Front Pharmacol. 2020 Jul 3;11:1007.

Haguet H, Graux C, Mullier F, Dogné JM, Douxfils J. Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis. Cancers (Basel). 2020 May 15;12(5):E1242.

Morimont L, Bouvy C, Delvigne AS, Dogné JM, Douxfils J. Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance. J Thromb Haemost. 2020 Apr;18(4):895-904.

Siriez R, Alpan L, Elasaad K, Devel P, Laloy J, Dogné JM, Douxfils J. Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method. J Thromb Thrombolysis. 2020 Apr;49(3):395-403.

Evrard J, Morimont L, Didembourg M, Haguet H, Siriez R, Dogné JM, Douxfils J. Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance. Int J Lab Hematol. 2020 Dec 12.

Siriez R, Evrard J, Dogné JM, Pochet L, Bouvy C, Lessire S, Mullier F, Douxfils J. Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. Int J Lab Hematol. 2019 Jan 3.

Contact

jonathan.douxfils@unamur.be